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Abstract
Purpose To evaluate criteria driving retreatment with ranibizumab in Italian patients with myopic choroidal neovascularization
(mCNV).
Methods OLIMPIC was a 12-month, phase IIIb, open-label study. Patients with active mCNV were treated with ranibizumab
0.5 mg according to the European label. The study assessed local criteria in Italy driving retreatment decisions with ranibizumab;
and the efficacy, safety, and tolerability of ranibizumab.
Results The mean (standard deviation [SD]) age of treated patients (N = 200) was 61.8 (12.7) years; range 22–85 years. The
multivariate regression model indicated that presence of active leakage (odds ratio [OR] 95% confidence interval [CI]: 11.30
[1.03–124.14]), presence of intraretinal fluid (OR [95%CI]: 28.21 [1.55–513.73]), and an improvement in best-corrected visual
acuity (BCVA) from baseline < 10 letters (OR [95%CI]: 17.60 [1.39–222.75]) were the factors with the greatest effect on
retreatment with ranibizumab. The mean (SD) BCVA gain from baseline to month 12 was 8.4 (12.8) letters (P < 0.0001). The
mean (SD) number of injections was 2.41 (1.53); range 1–9. Ocular and non-ocular adverse events were reported in 41 (20.5%)
and 30 (15.0%) patients, respectively.
Conclusions Individualized treatment with ranibizumab was effective in improving BCVA in patients with mCNV over
12 months. Both anatomical and functional variables had significant effects on causing retreatment. There were no new
safety findings.
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Introduction
Pathologic myopia (PM)—also known as high, degenerative,
or malignant myopia [1]—is characterized by a refractive er-
ror of ≥ − 6 Diopter (D); axial length ≥ 26 mm; and degener-
ative changes involving the sclera, choroid, and retina [2, 3].
PM affects mainly the younger population (age < 50 years)
[4–6], and is associated with a reduction in the quality of life
(QoL) of the affected patients and is a socio-economic burden
on society [7, 8]. Approximately 5–10% patients with PM
develop myopic choroidal neovascularization (mCNV) [8],
which is the most common vision-threatening complication
of PM. The long-term prognosis of mCNV is poor if left un-
treated [5, 9–11].
Vascular endothelial growth factor (VEGF) is thought
to have an important role in the pathogenesis of mCNV
as it triggers angiogenesis and its levels are increased in
eyes with mCNV [12–14]. Ranibizumab was the first
anti-VEGF agent to be approved for the treatment of
visual impairment secondary to mCNV based on the
results from the RADIANCE [15] and REPAIR [16,
17] studies, which demonstrated superior visual and an-
atomical outcomes with ranibizumab. Following an ini-
tial injection, the current label of ranibizumab 0.5 mg
for mCNV recommends monthly monitoring, and
retreatment is determined by the physician based on dis-
ease activity, as assessed by visual acuity (VA) and/or
anatomical parameters [18].
The OLIMPIC study (NCT02034006) [19] was designed
to assess local criteria in Italy driving retreatment decisions
with ranibizumab and to evaluate efficacy, safety, and tolera-
bility of ranibizumab in Italian patients diagnosed with visual
impairment due to mCNV.
Methods
Study design
OLIMPIC was a prospective, 12-month, phase IIIb, open-
label, interventional, multicenter study in patients with vi-
sual impairment due to mCNV. The study was conducted
from June 2014 to July 2016 across 33 centers in Italy (see
Table, Online resource 1, which shows the list of study
centers) and did not impose a fixed monthly visit scheme,
used for registrative trial. The design used is very close to
clinical practice.
The study was conducted in accordance with the
Declaration of Helsinki, and the study protocol (and all its
amendments) was reviewed by the Independent Ethics
Committee for each center. Patients provided written informed
consent before entering the study.
Patients
Participants ≥ 18 years of age were included if they were di-
agnosed with active mCNV (as confirmed by the presence of
high myopia with > − 6 D of spherical equivalence,
posterior changes compatible with PM detected by fundus
ophthalmoscopy and fundus photography, active leakage from
CNV observed through fluorescein angiography (FA), and
intra/subretinal fluid (IRF/SRF) observed using optical coher-
ence tomography (OCT)) and had a best-corrected visual acu-
ity (BCVA) > 24 and < 78 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters (Snellen equivalent of
approximately 20/32 to 20/320).
If both eyes were eligible, the eye with the worse VA at
baseline was selected for treatment, except when medical rea-
sons or local ethical requirements required selection of the eye
with better VA.
Patients were excluded if they had an active infectious dis-
ease or intraocular inflammation in either eye at the time of
enrolment; ocular disorders in the study eye requiring medical
or surgical intervention or resulting in compromised VA; re-
ceived pan-retinal or focal/grid laser photocoagulation with
involvement of the macular area in the study eye at any time;
or received intraocular treatment with any anti-VEGF,
verteporfin photodynamic therapy, or any intraocular surgery
or corticosteroid administration within 1 month before study
entry; uncontrolled blood pressure; or a history of stroke or
other medical conditions that could have influenced the study
outcome. Women of childbearing potential not using effective
methods of contraception, and pregnant or nursing women
were also excluded.
Treatment
All eligible patients received a single initial intravitreal injec-
tion of ranibizumab 0.5 mg as per the approved label [18].
Mandatory monitoring visits were planned monthly for the
first 3 months, and then at the 6 and 12 month after the first
administration of ranibizumab, with a tolerance of 7 days.
Optional visits could be possible outside of the pre-planned
visits, but were not tracked in the electronic case record form.
Further injections were administered if monitoring indicated
the presence of disease activity, based on functional and/or
anatomical features as per local clinical practice and as per
approved label.
Objectives
The primary objective was to investigate the current
criteria driving retreatment in Italian patients affected by
mCNV and experiencing a relapse of the disease after the
first administration of ranibizumab. Both anatomical (signs
of lesion activity evaluated through clinical examination and/
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or OCT, and/or FA) and/or functional (reduction in BCVA)
criteria were considered during the analysis.
The secondary objectives included evaluation of the mean
change in BCVA at months 6 and 12 compared with baseline;
the number of ranibizumab injections administered over the
12-month study period; time to relapse/retreatment; and safety
and tolerability.
Assessments
Efficacy
Both functional and anatomical parameters were assessed lo-
cally by investigators or trained technicians at each site.
Efficacy assessments were conducted before administration
of ranibizumab on the day of treatment.
BCVA: BCVAwas tested at each visit until month 12 using
the ETDRS charts. BCVA measurements were taken in a sit-
ting position at an initial test distance of 4 m using ETDRS
charts. Refractive error was expressed in D.
OCT: Central subfield thickness (CSFT); central subfield
volume (CSV); and presence of macular edema, IRF, cysts,
and SRF were assessed using OCTat screening and months 2,
6, and 12.
FA: Evidence of CNVand presence of active leakage were
assessed on FA at screening and months 2 and 6.
Clinically significant abnormalities assessed at fundus oph-
thalmoscopy and as per physician’s opinion (hemorrhage, pig-
ment clumping, retinal pigment epithelium atrophy).
Safety
All adverse events (AEs) and serious adverse events (SAEs)
were assessed over the entire 12-month study duration.
Statistical analysis
The planned sample size was 200 patients; assuming around
70% of patients would need retreatment, this meant that the
primary endpoint could be evaluated in approximately 140
patients.
For the primary endpoint, a multivariate regression model
was fitted considering the following covariates, using a step-
wise procedure: presence of IRF (yes/no); presence ofmacular
edema (yes/no); presence of cysts (yes/no); presence of active
leakage (yes/no); presence of SRF (yes/no); clinically signif-
icant abnormalities, defined as any abnormal signal at the
fundus examination, performed at each time point, assessed
bymeans of a slit lamp and indirect stereo ophthalmoscope, as
per clinical judgment (yes/no); change in macular volume
versus previous visit; change in central retinal thickness ver-
sus previous visit; an improvement in BCVA < 5 letters (yes/
no); an improvement in BCVA < 10 letters (yes/no); and
change from baseline in BCVA classified as worsened (loss
of ≥ 5 letters), stable (loss of ≥ 4 letters to gain of ≤ 4 letters),
or improved (gain of ≥ 5 letters). A significance level of 0.3
was required to allow a variable into the model, and a signif-
icance level of 0.35was required for a variable to remain in the
model. Moreover, a univariate logistic regression model was
applied to each of the aforementioned covariates.
A sensitivity analysis was then performed at month 2,
which considered a patient as retreated if their first retreatment
took place < 30 days after the month 2 assessment, in order to
better evaluate the effect of each covariate. For all analyses,
the independent variables were considered at the closest
timepoint to the first retreatment. In case a value was not
recorded at the scheduled assessment, the value was consid-
ered missing.
AWilcoxon signed rank test was used to analyze changes
in BCVA. AWilcoxon/Mann-WhitneyU test was used in case
of non-normally distributed data for comparison of naïve ver-
sus treated patients. OCT and FA parameters were summa-
rized using descriptive statistics. Time to retreatment in days
was presented overall by Kaplan-Meier estimates and summa-
rized by median, 25th and 75th percentiles, and their 95%
confidence interval (CI). Efficacy was analyzed in the full
analysis set (FAS) which included all patients who received
at least one dose of ranibizumab.
Safety was analyzed in the safety analysis set which includ-
ed all patients who received at least one dose of ranibizumab
and had at least one post-baseline safety assessment. The safe-
ty results were summarized.
All analyses were carried out using SAS® for Windows
release 9.4 (64-bit) or later (SAS Institute Inc., Cary, NC,
USA).
Results
Of the 215 patients screened, 200 patients underwent a base-
line visit and received one injection of ranibizumab 0.5 mg.
All 200 patients were included in the FAS and safety set.
Fourteen (7%) patients discontinued the study before the 12-
month study visit. The reasons for discontinuation were con-
sent withdrawn (n = 7), lost to follow-up (n = 5), death (n = 1),
and pregnancy (n = 1, Fig. 1).
The mean (± standard deviation [SD]) age of the patients
was 61.8 (12.7) years (range 22–85 years), 73.5% were fe-
male, and 99.5% patients were Caucasian. Bilateral PM was
present in 79.5% patients and bilateral CNV in 13% patients.
The most common CNV subtype observed was subfoveal
CNV (61.0% patients). Median time from CNV diagnosis to
informed consent was 0.89 (Interquartile range 0.10–
14.74 months) (Table 1).
Of the 200 patients, 147 (73.5%) were anti-VEGF treat-
ment-naїve at baseline. During the study, 70 (35%) patients
were treated with ranibizumab 0.5 mg only once (defined as
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treated patients), and 130 (65%) patients were treated with
ranibizumab more than once (defined as retreated patients).
There were no differences in baseline characteristics between
the treated and retreated cohorts or between the prior anti-
VEGF treated and treatment-naïve cohorts (Table 1).
Efficacy
The multivariate regression model indicated presence of ac-
tive leakage (OR [95%CI]: 11.30 [1.03–124.14]), presence of
IRF (OR [95%CI]: 28.21 [1.55–513.73]), and an improve-
ment in BCVA from baseline < 10 letters (OR [95%CI]:
17.60 [1.39–222.75]) to be the factors with the greatest effect
on retreatment. The univariate model analysis indicated mac-
ular edema (P < 0.0001), presence of active leakage (P <
0.0001), presence of cysts (P < 0.0001), presence of IRF
(P < 0.0001), presence of clinically significant abnormalities
(P = 0.0103), and an improvement in BCVA of < 10 letters
from baseline (P = 0.0114) to be the factors with a statistically
significant association to retreatment (Fig. 2).
The sensitivity analysis at month 2 based on the mul-
tivariate regression model confirmed the presence of IRF
and active leakage at month 2 to be the factors most
likely to drive retreatment. The univariate model showed
the presence of active leakage, IRF, SRF, cysts, and
macular edema to be the factors strongly associated with
retreatment.
BCVA outcomes
There was a notable gain in mean (SD) BCVA from base-
line (54.66 [16.86]) to month 6 and to month 12 (7.51
[11.68] and 8.42 [12.81] ETDRS letters, respectively, both
P < 0.0001, Fig. 3). The mean (SD) BCVA at baseline in
patients who were anti-VEGF treatment-naïve or anti-
VEGF-treated was 54.93 (17.00) and 53.89 (16.61) letters,
respectively. The gain from baseline to month 12 or time of
premature discontinuation was similar in patients who were
prior anti-VEGF treatment-naïve or anti-VEGF-treated (8.32
[13.41] and 8.69 [11.12] ETDRS letters, respectively, both
P < 0.0001, Fig. 3).
At month 12 or premature discontinuation, the proportion
of patients gaining ≥ 5 and ≥ 10 ETDRS letters in the treated/
retreated cohorts was 84.3/75.0% and 54.9/52.2%,
respectively.
The mean (SD) refractive error remained stable in the
study eye over the study duration, − 7.25 (6.09) D at
baseline versus − 7.28 (6.51) D at month 12 or premature
study discontinuation.
Anatomical outcomes
The foveal thickness decreased over time, and the mean (SD)
change in CSFT from baseline (361.57 [92.16] μm) to months
6 and 12 or premature discontinuation was − 41.45 (77.88)
and − 35.72 (95.28) μm, respectively (both P < 0.0001;
Fig. 4). The mean (SD) CSFT at baseline was 335.98
(97.64) μm in the treated cohort and 374.97 (86.56) μm in
the retreated cohort. The mean change in CSFT from baseline
to month 12 was higher in retreated patients compared with
treated patients (Fig. 4).The mean (SD) change in CSV from
baseline (0.28 [0.07] mm3) at months 6 and 12 was − 0.02
(0.07) mm3 and − 0.02 (0.09) mm3, respectively (both P <
0.0001). The mean (SD) CSVat baseline was 0.27 (0.08) mm3
in the treated cohort and 0.29 (0.07) mm3 in the retreated
cohort; the reduction in CSVat month 12 was similar in treat-
ed and retreated patients (− 0.02 [0.07] mm3 and − 0.01 [0.10]
mm3, respectively).
The proportion of patients with macular edema, SRF, IRF,
and cysts decreased from baseline to month 12 or premature
discontinuation (see Fig, Online resource 2, which shows the
proportion of patients with macular edema, SRF, IRF, and
Fig. 1 Patient disposition
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cysts during the study). The reduction in these anatomical
parameters was more prominent in treated patients compared
with retreated patients (see Fig, Online resource 2).
FA characteristics
At baseline, most patients underwent FA (187/200, 93.5%),
and all, except 1 (1.56%) patient in treated cohort, had evi-
dence of active CNV; this proportion decreased at month 2
(n = 121/180; 67.2%) and month 6 (n = 118/175; 67.4%) after
ranibizumab treatment. The reduction from baseline at months
2 and 6 was observed in both treated and retreated cohorts.
At baseline, 182 of 187 patients undergoing FA (97.3%)
showed active leakage. This proportion decreased at month 2
(n = 59/180; 32.8%) and month 6 (n = 44/175; 25.1%) after
ranibizumab treatment (see Fig, Online resource 3, which
shows the proportion of patients with active leakage from
baseline to month 6).The reduction was observed in both treat-
ed and retreated cohorts at months 2 and 6 (see Fig, Online
resource 3).
Treatment exposure
The mean (SD) number of injections in the FAS was 2.41
(1.53); range 1–9, the mean (SD) number of injections per
retreated patient was 3.17 (1.40). Overall, 26.5%, 19.5%,
and 8.5% of patients received two, three, or four injections,
respectively, prior to month 12. Kaplan-Meier analysis of time
to first retreatment showed that the median time for a patient to
be free from retreatment was 3.15 months (95%CI: 2.33,
5.09 months, Fig. 5). This median time to relapse was similar
in those who were anti-VEGF treatment-naïve or anti-VEGF-
treated at baseline (3.19 and 3.15months, respectively, Fig. 5).
Safety
Overall, at least one ocular or non-ocular AE was reported in
41 (20.5%) and 30 (15.0%) patients, respectively. Ocular
SAEs were reported in two patients and non-ocular SAEs
were reported in five patients (Table 2). Two AEs were
suspected to be related to ranibizumab; both were ocular
events (see Table, Online resource 4, which lists the drug-
related AEs).
Two AEs, both non-ocular events (maternal exposure dur-
ing delivery and spontaneous abortion) that occurred in one
and the same patient, resulted in study discontinuation. Both
events were suspected to be not related to ranibizumab. There
were no cases of endophthalmitis. One death was reported
during the study (due to cardiac arrest) and was considered
by the investigator to be not related to treatment.Ta
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Discussion
The current European label for ranibizumab recommends in-
dividualized treatment based on disease activity, as assessed
by VA and/or anatomical parameters, for patients with visual
impairment due to mCNV [18]. In the OLIMPIC study, the
results of the multivariate analysis showed two anatomical
parameters (active leakage and IRF) and one VA parameter
(improvement in BCVA from baseline < 10 letters) to be the
factors most likely to drive retreatment. This finding was
confirmed by the univariate model analysis results; of the 6
factors shown to drive retreatment, five were anatomical and
the sixth was an improvement in BCVA from baseline < 10
letters. The sensitivity analyses performed at month 2 (both
univariate and multivariate regression models) also showed
anatomical parameters to be the main criteria driving
retreatment.
The baseline characteristics of patients in this study were
generally consistent with those reported previously in mCNV
patients [15, 16, 20–22], in that most patients were female and
Fig. 2 Criteria driving
retreatment (full analysis set).
Univariate logistic regression
model. BCVA, best-corrected
visual acuity; LCL, lower
confidence limit; OR, odds ratio;
UCL, upper confidence limit
Fig. 3 BCVA gain from baseline
to month 12 or premature
discontinuation (full analysis set).
BCVA, best-corrected visual
acuity; ETDRS, Early Treatment
Diabetic Retinopathy Study;
VEGF, vascular endothelial
growth factor
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the location of CNV was subfoveal in the majority of patients.
However, patients in this study were older than those in the
RADIANCE study (mean age ~ 62 years in OLIMPIC vs ~
56 years in RADIANCE [15]). Ranibizumab treatment result-
ed in notable BCVA improvements at month 12 (+ 8.42 let-
ters), which corroborated the benefits observed with
ranibizumab in the RADIANCE and REPAIR studies (+
14.4 letters and + 13.8 letters, respectively) [15, 17]. The near-
ly 1-line lower VA gain in OLIMPIC than that observed in
RADIANCE could be related to the fact that patients enrolled
in the OLIMPIC study were older, and a higher proportion had
non-subfoveal lesions (61% in OLIMPIC vs ~ 70% in
RADIANCE); also both treated and treatment-naïve patients
were included. The VA improvements with ranibizumab have
been shown to be maintained over the long term for up to
4 years in mCNV patients [23–26].
In patients with mCNV, it has been observed that VA
improvements with ranibizumab occur irrespective of
whether patients are treatment-naïve at baseline or not [27],
whereas in other indications, better VA outcomes with
ranibizumab treatment have been observed in treatment-
naïve patients, which could be related to the difference in
Fig. 4 CSFT reduction from
baseline to month 12 or premature
discontinuation (full analysis set)
CSFT, central subfoveal thickness
Fig. 5 Time to first retreatment
(full analysis set) Kaplan-Meier
curves showing number of
patients at risk. CI, confidence
interval; VEGF, vascular
endothelial growth factor
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etiology of mCNV. Similarly, in the OLIMPIC study, there
were no notable between-group differences, although the
BCVA gain was numerically higher in anti-VEGF treatment-
naïve patients.
In elderly patients, the inability to differentiate if CNV is
related to pathologic myopia or to age-related macular degen-
eration is a known bias. In the pivotal phase 3 trials of
ranibizumab and aflibercept in mCNV [15, 28], there were
no upper limit in age for patient recruitment. In both the phase
3 studies, as well as the OLIMPIC study, all patients’ ≥
18 years of age were eligible if affected with pathologic
myopia and CNV. The mean (SD) age at baseline in the
OLIMPIC study was 61.8 (12.7) years, range 22–85 years;
in the ranibizumab groups in RADIANCE study was 54.0
(14.0) years, range 18–87 years (data on file) in group I and
56.1 (14.4) years, range 19–85 years (data on file) in group II;
and in the aflibercept group in MYRROR study was 58.5
(13.17) years, range 23–87 years. As the inclusion criteria in
the OLIMPIC study was similar to that in RADIANCE [15]
and MYRROR [28], it has more or less the same bias with
relation to age as that observed in the phase 3, registration
studies that led to approval of ranibizumab and aflibercept
for mCNV.
The anatomical outcomes corroborated with the BCVA im-
provements: there was a rapid reduction in CSFT at month 3
that gradually reduced further up to month 12. The change in
CSFT was more prominent in retreated patients. The propor-
tion of patients with macular edema, SRF, IRF, cysts, and
active leakage also decreased over time. FA is considered
the current standard of care for evaluating mCNV activity
[23, 29, 30]. Most patients (93.5%) underwent FA analysis
at screening in our study and all except one patient had evi-
dence of mCNV. Ranibizumab treatment was associated with
a reduction in the proportion of patients with active CNVand
active leakage over time. In mCNV, the decision regarding
retreatment needs a comprehensive approach to the disease.
Although perception of metamorphopsia, VA changes, fundus
examination, and OCTare often sufficient to indicate the need
for retreatment, FA is an important tool to guide retreatment
decisions for active mCNV [23, 29, 30].
Previous studies in patients with mCNV have shown that,
on average, patients may require one to four anti-VEGF injec-
tions during the first year of treatment [15, 17, 27, 31–33].
Consistent with these reports, in our study, the mean number
of ranibizumab injections was 2.41 over 12 months. After the
mandatory first injection, 35% of patients did not require an-
other injection, and 46% of patients required only one or two
additional injections over the 12-month duration. The median
treatment-free interval was 3.15 months, indicating that pa-
tients with mCNV may need less frequent monitoring com-
pared with other ocular disorders.
The safety findings were consistent with the safety results
from the pivotal trials and the known safety profile of
ranibizumab [15–18]. The incidence of serious ocular and non-
ocular AEs was low. There were no cases of endophthalmitis.
The limitations of the study are its open-label nature and
lack of a placebo control. Furthermore, the study did not in-
clude classification of the staphyloma subtype. Although
functional and anatomical outcomes were assessed in the
study according to protocol, OCT and FAwere not performed
at each study visit, and FAwas not assessed at the 12-month
visit. Moreover, no central reading center was involved in the
assessment of OCT and FA outcomes: despite procedures be-
ing described in the study protocol, a certain amount of
Table 2 Key ocular and non-ocular AEs and SAEs (safety set)
Preferred term, n (%)* Ranibizumab 0.5
mg (N = 200)
Ocular AEs, total† 41 (20.5)
CNV 7 (3.5)
Conjunctival hemorrhage 4 (2.0)
Conjunctival hyperemia 2 (1.0)
Metamorphopsia 2 (1.0)
Retinal hemorrhage 2 (1.0)
VA reduced 2 (1.0)
Expired product administered 2 (1.0)
Non-ocular AEs, total† 30 (15.0)
Influenza 7 (3.5)
Headache 2 (1.0)
Hypertension 2 (1.0)
C-reactive protein abnormal 2 (1.0)
Ocular SAEs, total 2 (1.0)
Expired product administered$ 2 (1.0)
Non-ocular SAEs, total 5 (2.5)
Atrioventricular block 1 (0.5)
Cardiac arrest 1 (0.5)
Cholecystitis acute 1 (0.5)
Klebsiella sepsis 1 (0.5)
Spontaneous abortion 1 (0.5)
Ovarian cyst 1 (0.5)
Terms were coded using Medical Dictionary for Regulatory Activities
dictionary, version 18.1.
AE, adverse event; CNV, choroidal neovascularization; SAE, serious ad-
verse event; VA, visual acuity
*Each patient could experience more than one AE/SAE. Patients were
counted only once in each row
† Patients with at least one event
$ One patient received the expired study medication by mistake nearly
11 months after starting study medication. The patient reported no sys-
temic or local AE’s as a consequence of the injection and recovered on the
same day. No action was taken with regard to study medication due to the
event. The other patient received the expired studymedication bymistake
5 months and few days after starting study medication. No treatment was
administered due to the event and no action was taken with regard to
study medication. The patient completely recovered from the event on
the same day
766 Graefes Arch Clin Exp Ophthalmol (2019) 257:759–768
variability in the assessment could be possible, in particular
regarding potential overlapping criteria such as IRF, macular
edema or intraretinal cysts, impacting the final anatomical
outcomes and evaluation of the primary endpoint.
In conclusion, the OLIMPIC study confirmed that individ-
ualized treatment with ranibizumab is effective in improving
and sustaining BCVA in patients with myopic CNV over
12 months. Many patients may only need one or two injec-
tions during the first year. Based on disease activity, the need
for retreatment can be assessed by VA and/or anatomical pa-
rameters, but the latter were found to be the factors most likely
to drive retreatment in this study.
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